

Michael John Gill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6485364/publications.pdf>

Version: 2024-02-01

174
papers

11,361
citations

47409

49
h-index

34195

103
g-index

175
all docs

175
docs citations

175
times ranked

12753
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. <i>Lancet, The</i> , 2002, 360, 119-129.	6.3	1,415
2	Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada. <i>PLoS ONE</i> , 2013, 8, e81355.	1.1	1,111
3	Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival. <i>New England Journal of Medicine</i> , 2009, 360, 1815-1826.	13.9	986
4	Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. <i>Lancet HIV,the</i> , 2017, 4, e349-e356.	2.1	805
5	Risk of Anal Cancer in HIV-Infected and HIV-Uninfected Individuals in North America. <i>Clinical Infectious Diseases</i> , 2012, 54, 1026-1034.	2.9	453
6	A Comparison of Two Regimens for the Treatment of <i>Mycobacterium avium</i> Complex Bacteremia in AIDS: Rifabutin, Ethambutol, and Clarithromycin versus Rifampin, Ethambutol, Clofazimine, and Ciprofloxacin. <i>New England Journal of Medicine</i> , 1996, 335, 377-384.	13.9	304
7	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. <i>Lancet, The</i> , 2004, 364, 51-62.	6.3	303
8	Cumulative Incidence of Cancer Among Persons With HIV in North America. <i>Annals of Internal Medicine</i> , 2015, 163, 507-518.	2.0	271
9	Late Presentation for Human Immunodeficiency Virus Care in the United States and Canada. <i>Clinical Infectious Diseases</i> , 2010, 50, 1512-1520.	2.9	187
10	Invasive Cervical Cancer Risk Among HIV-Infected Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 405-413.	0.9	184
11	Cohort Profile: The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). <i>International Journal of Epidemiology</i> , 2007, 36, 294-301.	0.9	176
12	Human immunodeficiency virus type 1 Nef protein mediates neural cell death: a neurotoxic role for IP-10. <i>Virology</i> , 2004, 329, 302-318.	1.1	158
13	Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. <i>Aids</i> , 1998, 12, 2161-2167.	1.0	142
14	End-Stage Renal Disease Among HIV-Infected Adults in North America. <i>Clinical Infectious Diseases</i> , 2015, 60, 941-949.	2.9	142
15	Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2014, 59, 287-297.	2.9	136
16	Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: Protease inhibitor-mediated neurotoxicity. <i>Annals of Neurology</i> , 2006, 59, 816-824.	2.8	131
17	Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States. <i>Clinical Infectious Diseases</i> , 2018, 66, 1230-1238.	2.9	131
18	HIV Infection of the Central Nervous System: Clinical Features and Neuropathogenesis. <i>Neurologic Clinics</i> , 2008, 26, 799-819.	0.8	127

#	ARTICLE	IF	CITATIONS
19	Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000–2010. <i>Journal of Infectious Diseases</i> , 2016, 214, 862-872.	1.9	116
20	Compartmentalization of the gut viral reservoir in HIV-1 infected patients. <i>Retrovirology</i> , 2007, 4, 87.	0.9	106
21	Virologic and immunologic response to HAART, by age and regimen class. <i>Aids</i> , 2010, 24, 2469-2479.	1.0	92
22	Trends and Disparities in Antiretroviral Therapy Initiation and Virologic Suppression Among Newly Treatment-Eligible HIV-Infected Individuals in North America, 2001–2009. <i>Clinical Infectious Diseases</i> , 2013, 56, 1174-1182.	2.9	90
23	Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy. <i>PLoS ONE</i> , 2016, 11, e0160460.	1.1	86
24	Evaluation of brief screening tools for neurocognitive impairment in HIV/AIDS. <i>Aids</i> , 2013, 27, 2385-2401.	1.0	82
25	Cytotoxic CD4+ T cells use granulysin to kill <i>Cryptococcus neoformans</i> , and activation of this pathway is defective in HIV patients. <i>Blood</i> , 2007, 109, 2049-2057.	0.6	79
26	Changes Over Time in Risk of Initial Virological Failure of Combination Antiretroviral Therapy. <i>Archives of Internal Medicine</i> , 2006, 166, 521.	4.3	77
27	Incidence and risk factors of HPV-related and HPV-unrelated Head and Neck Squamous Cell Carcinoma in HIV-infected individuals. <i>Oral Oncology</i> , 2014, 50, 1169-1176.	0.8	77
28	The persisting burden of invasive pneumococcal disease in HIV patients: an observational cohort study. <i>BMC Infectious Diseases</i> , 2011, 11, 314.	1.3	76
29	Accelerated replicative senescence of the peripheral immune system induced by HIV infection. <i>Aids</i> , 2000, 14, 771-780.	1.0	75
30	CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). <i>Clinical Infectious Diseases</i> , 2017, 65, 959-966.	2.9	75
31	CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?. <i>AIDS Research and Therapy</i> , 2010, 7, 45.	0.7	73
32	Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002–2009. <i>Aids</i> , 2013, 27, 803-813.	1.0	70
33	Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients. <i>PLoS ONE</i> , 2016, 11, e0148231.	1.1	70
34	Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. <i>Aids</i> , 2009, 23, 1689-1699.	1.0	69
35	Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America. <i>Clinical Infectious Diseases</i> , 2017, 65, 636-643. The Direct Medical Costs of Late Presentation ($T_j ETQq0 0 0 rgBT /Overlock 10 Tf 50 82 Td$ (xmlns:mml="http://www.w3.org/1998/Math/MathML">)	2.9	67
36	15-Year Period. <i>AIDS Research and Treatment</i> , 2012, 2012, 1-8.	0.3	65

#	ARTICLE	IF	CITATIONS
37	Disparities in the Quality of HIV Care When Using US Department of Health and Human Services Indicators. <i>Clinical Infectious Diseases</i> , 2014, 58, 1185-1189.	2.9	65
38	How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?. <i>Clinical Infectious Diseases</i> , 2016, 62, 919-926.	2.9	65
39	Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). <i>International Journal of Epidemiology</i> , 2014, 43, 691-702.	0.9	64
40	HIV Infection, Immunosuppression, and Age at Diagnosis of Non-AIDS-Defining Cancers. <i>Clinical Infectious Diseases</i> , 2016, 64, ciw764.	2.9	63
41	Growth hormone prevents human immunodeficiency virus-induced neuronal p53 expression. <i>Annals of Neurology</i> , 2003, 54, 605-614.	2.8	60
42	Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw531.	2.9	60
43	Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain. <i>Retrovirology</i> , 2017, 14, 47.	0.9	57
44	Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study. <i>Journal of NeuroVirology</i> , 2016, 22, 349-357.	1.0	56
45	Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapy-Experienced Patients with HIV Infection in North America. <i>Clinical Infectious Diseases</i> , 2009, 49, 1582-1590.	2.9	55
46	Hepatitis C virus co-infection increases neurocognitive impairment severity and risk of death in treated HIV/AIDS. <i>Journal of the Neurological Sciences</i> , 2012, 312, 45-51.	0.3	55
47	Comparison of the RealTime HIV-1, COBAS TaqMan 48 v1.0, Easy Q v1.2, and Versant v3.0 assays for Determination of HIV-1 Viral Loads in a Cohort of Canadian Patients with Diverse HIV Subtype Infections. <i>Journal of Clinical Microbiology</i> , 2011, 49, 118-124.	1.8	53
48	Intimate Partner Violence and HIV: A Review. <i>Current HIV/AIDS Reports</i> , 2013, 10, 380-389.	1.1	52
49	Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. <i>Clinical Infectious Diseases</i> , 2016, 62, 1571-1577.	2.9	52
50	Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. <i>Aids</i> , 2008, 22, 2461-2469.	1.0	51
51	Changing Epidemiology and Risk Factors for Gastrointestinal Non-Hodgkin's Lymphoma in a North American Population: Population-Based Study. <i>American Journal of Gastroenterology</i> , 2008, 103, 1762-1769.	0.2	48
52	Prevalence, clinical associations, and impact of intimate partner violence among HIV-infected gay and bisexual men: a population-based study. <i>HIV Medicine</i> , 2013, 14, 293-302.	1.0	48
53	Domestic Violence Screening: Prevalence and Outcomes in a Canadian HIV Population. <i>AIDS Patient Care and STDs</i> , 2010, 24, 763-770.	1.1	47
54	Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study. <i>Lancet HIV</i> , 2019, 6, e240-e249.	2.1	46

#	ARTICLE	IF	CITATIONS
55	Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. <i>Aids</i> , 1998, 12, F103-F109.	1.0	45
56	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 1316-1326.	2.9	44
57	<i>Rhodococcus equi</i> —An easily missed opportunistic pathogen. <i>Scandinavian Journal of Infectious Diseases</i> , 1991, 23, 1-6.	1.5	43
58	HIV-1 viral diversity and its implications for viral load testing: review of current platforms. <i>International Journal of Infectious Diseases</i> , 2011, 15, e661-e670.	1.5	43
59	Hepatitis C Viremia and the Risk of Chronic Kidney Disease in HIV-Infected Individuals. <i>Journal of Infectious Diseases</i> , 2013, 208, 1240-1249.	1.9	43
60	The Impact of Non-Antiretroviral Polypharmacy on the Continuity of Antiretroviral Therapy (ART) Among HIV Patients. <i>AIDS Patient Care and STDs</i> , 2016, 30, 11-17.	1.1	43
61	HIV dementia patients exhibit reduced viral neutralization and increased envelope sequence diversity in blood and brain. <i>Aids</i> , 2002, 16, 1905-1914.	1.0	39
62	Plasma microRNA profiling predicts HIV-associated neurocognitive disorder. <i>Aids</i> , 2016, 30, 2021-2031.	1.0	38
63	Active Immunization of Patients with HIV Infection: A Study of the Effect of VaxSyn, a Recombinant HIV Envelope Subunit Vaccine, on Progression of Immunodeficiency. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 483-490.	0.5	37
64	Inflammation and epithelial cell injury in AIDS enteropathy: involvement of endoplasmic reticulum stress. <i>FASEB Journal</i> , 2011, 25, 2211-2220.	0.2	37
65	First occurrence of diabetes, chronic kidney disease, and hypertension among North American HIV-infected adults, 2000-2013. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw804.	2.9	37
66	Herpes simplex virus infection of the hand. <i>Journal of the American Academy of Dermatology</i> , 1990, 22, 111-116.	0.6	35
67	Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. <i>International Journal of Epidemiology</i> , 2012, 41, 1807-1820.	0.9	34
68	Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening. <i>Journal of Infectious Diseases</i> , 2011, 204, 893-901.	1.9	33
69	Life-Expectancy Disparities Among Adults With HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model. <i>American Journal of Epidemiology</i> , 2019, 188, 2097-2109.	1.6	32
70	Gastrointestinal tissue cultures for HIV in HIV-infected/AIDS patients. <i>Aids</i> , 1992, 6, 553-556.	1.0	28
71	Influence of Geographical Origin and Ethnicity on Mortality in Patients on Antiretroviral Therapy in Canada, Europe, and the United States. <i>Clinical Infectious Diseases</i> , 2013, 56, 1800-1809.	2.9	28
72	HIV-associated sensory polyneuropathy and neuronal injury are associated with miRNA-455-3p induction. <i>JCI Insight</i> , 2018, 3, .	2.3	28

#	ARTICLE	IF	CITATIONS
73	Association of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia With Anal Cancer Risk in Persons Living With HIV in the United States and Canada. <i>Clinical Infectious Diseases</i> , 2020, 70, 1176-1185.	2.9	27
74	Lifetime antiretroviral exposure and neurocognitive impairment in HIV. <i>Journal of NeuroVirology</i> , 2020, 26, 743-753.	1.0	26
75	Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. <i>JAMA Network Open</i> , 2021, 4, e2037512.	2.8	26
76	CD4/CD8 Ratio and Cancer Risk Among Adults With HIV. <i>Journal of the National Cancer Institute</i> , 2022, 114, 854-862.	3.0	26
77	Does In Vitro Susceptibility to Rifabutin and Ethambutol Predict the Response to Treatment of <i>Mycobacterium avium</i> Complex Bacteremia with Rifabutin, Ethambutol, and Clarithromycin?. <i>Clinical Infectious Diseases</i> , 1998, 27, 1401-1405.	2.9	25
78	Antiretroviral Medication Adherence and Persistence with Respect to Adherence Tool Usage. <i>AIDS Patient Care and STDs</i> , 2000, 14, 351-358.	1.1	25
79	The five-year impact of an evolving global epidemic, changing migration patterns, and policy changes in a regional Canadian HIV population. <i>Health Policy</i> , 2009, 90, 296-302.	1.4	25
80	Impact of current antiretroviral therapies on neuroAIDS. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 371-374.	2.0	25
81	Avascular necrosis in HIV infection. <i>Aids</i> , 1999, 13, 1997.	1.0	25
82	Virological characteristics of occult hepatitis B virus in a North American cohort of human immunodeficiency virus type 1-positive patients on dual active anti-HBV/HIV therapy. <i>Journal of Clinical Virology</i> , 2014, 60, 347-353.	1.6	23
83	Role of viral evolutionary rate in HIV-1 disease progression in a linked cohort. <i>Retrovirology</i> , 2005, 2, 41.	0.9	22
84	Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 72, 1900-1909.	2.9	22
85	Associations between Depressive Symptomatology and Neurocognitive Impairment in HIV/AIDS. <i>Canadian Journal of Psychiatry</i> , 2018, 63, 329-336.	0.9	21
86	Neuropsychiatric disorders in HIV infection: impact of diagnosis on economic costs of care. <i>Aids</i> , 2006, 20, 2005-2009.	1.0	20
87	Evaluating the Impact of Functional Genetic Variation on HIV-1 Control. <i>Journal of Infectious Diseases</i> , 2017, 216, 1063-1069.	1.9	20
88	Short Communication: Identification of a Novel HIV Type 1 Subtype H/J Recombinant in Canada with Discordant HIV Viral Load (RNA) Values in Three Different Commercial Assays. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1309-1313.	0.5	19
89	Comparative Effectiveness of Initial Antiretroviral Therapy Regimens. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 58, 253-260.	0.9	19
90	Implementing an Intimate Partner Violence (IPV) Screening Protocol in HIV Care. <i>AIDS Patient Care and STDs</i> , 2015, 29, 133-141.	1.1	19

#	ARTICLE	IF	CITATIONS
91	Neurotoxicity of acyclovir in end stage renal disease. <i>Journal of Antimicrobial Chemotherapy</i> , 1990, 25, 300-300.	1.3	18
92	Absence of an Association Between Enteric Parasites in the Manifestations and Pathogenesis of HIV Enteropathy in Gay Men. <i>Scandinavian Journal of Infectious Diseases</i> , 1992, 24, 567-575.	1.5	18
93	Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?. <i>Aids</i> , 2008, 22, 2481-2492.	1.0	18
94	Brief Report: Cutaneous Melanoma Risk Among People With HIV in the United States and Canada. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 499-504.	0.9	17
95	A potentially preventable case of serious influenza infection in a pregnant patient. <i>Cmaj</i> , 2007, 177, 851-853.	0.9	16
96	Higher levels of Zidovudine resistant HIV in the colon compared to blood and other gastrointestinal compartments in HIV infection. <i>Retrovirology</i> , 2010, 7, 74.	0.9	16
97	Survival Outcomes and Effect of Early vs. Deferred cART Among HIV-Infected Patients Diagnosed at the Time of an AIDS-Defining Event: A Cohort Analysis. <i>PLoS ONE</i> , 2011, 6, e26009.	1.1	16
98	Uptake of Combination Antiretroviral Therapy and HIV Disease Progression According to Geographical Origin in Seroconverters in Europe, Canada, and Australia. <i>Clinical Infectious Diseases</i> , 2012, 54, 111-118.	2.9	16
99	HIV misdiagnosis: A root cause analysis leading to improvements in HIV diagnosis and patient care. <i>Journal of Clinical Virology</i> , 2017, 96, 84-88.	1.6	16
100	Increasing incidence of syphilis among patients engaged in HIV care in Alberta, Canada: a retrospective clinic-based cohort study. <i>BMC Infectious Diseases</i> , 2018, 18, 125.	1.3	16
101	A retrospective study of the clinical features of new syphilis infections in an HIV-positive cohort in Alberta, Canada. <i>BMJ Open</i> , 2018, 8, e021544.	0.8	16
102	Empiric neurocognitive performance profile discovery and interpretation in HIV infection. <i>Journal of NeuroVirology</i> , 2019, 25, 72-84.	1.0	16
103	Machine learning models reveal neurocognitive impairment type and prevalence are associated with distinct variables in HIV/AIDS. <i>Journal of NeuroVirology</i> , 2020, 26, 41-51.	1.0	16
104	Full-Length HIV Type 1 Genome Analysis Showing Evidence for HIV Type 1 Transmission from a Nonprogressor to Two Recipients Who Progressed to AIDS. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 575-579.	0.5	15
105	Clinical outcomes and immune benefits of anti-epileptic drug therapy in HIV/AIDS. <i>BMC Neurology</i> , 2010, 10, 44.	0.8	15
106	Adverse Health Effects for Individuals Who Move Between HIV Care Centers. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 57, 51-54.	0.9	15
107	The Cost of Antiretroviral Drug Resistance in HIV-Positive Patients. <i>Antiviral Therapy</i> , 2014, 19, 341-348.	0.6	14
108	Tobacco Smoking Is Not Associated With Accelerated Liver Disease in Human Immunodeficiency Virus-Hepatitis C Coinfection: A Longitudinal Cohort Analysis. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw050.	0.4	14

#	ARTICLE	IF	CITATIONS
109	An approach to conference selection and evaluation: advice to avoid "predatory" conferences. <i>Scientometrics</i> , 2019, 118, 687-698.	1.6	14
110	Improved Survival and Reduced Clinical Progression in HIV-Infected Patients with Advanced Disease Treated with Saquinavir plus Zalcitabine. <i>Antiviral Therapy</i> , 1998, 3, 33-42.	0.6	14
111	Decision making under explicit risk is impaired in individuals with human immunodeficiency virus (HIV). <i>Journal of Clinical and Experimental Neuropsychology</i> , 2015, 37, 733-750.	0.8	13
112	Combating the HIV reservoirs. <i>Biotechnology and Genetic Engineering Reviews</i> , 2018, 34, 76-89.	2.4	13
113	Efavirenz dosing in patients receiving continuous ambulatory peritoneal dialysis. <i>Aids</i> , 2000, 14, 1062.	1.0	13
114	Childhood Lymphadenitis in a Harsh Northern Climate due to Atypical Mycobacteria. <i>Scandinavian Journal of Infectious Diseases</i> , 1987, 19, 77-83.	1.5	12
115	Z-FA-FMK as a novel potent inhibitor of reovirus pathogenesis and oncolysis <i>in vivo</i> . <i>Antiviral Therapy</i> , 2010, 15, 897-905.	0.6	12
116	Managing HIV infection in patients older than 50 years. <i>Cmaj</i> , 2018, 190, E1253-E1258.	0.9	12
117	Cytomegalovirus Disease in HIV Infection: Twenty Years of a Regional Population's Experience. <i>Clinical Infectious Diseases</i> , 2006, 42, 1808-1809.	2.9	11
118	Discrepancies in Assignment of Subtype/Recombinant Forms by Genotyping Programs for HIV Type 1 Drug Resistance Testing May Falsely Predict Superinfection. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 995-1002.	0.5	11
119	Montreal Cognitive Assessment Performance in HIV/AIDS: Impact of Systemic Factors. <i>Canadian Journal of Neurological Sciences</i> , 2016, 43, 157-162.	0.3	11
120	Lymphocyte Membrane Modifications Induced by HIV Infection.. <i>Tohoku Journal of Experimental Medicine</i> , 1994, 173, 115-131.	0.5	10
121	An avoidable transmission of HIV from mother to child. <i>Cmaj</i> , 2011, 183, 690-692.	0.9	10
122	Understanding the delay in starting antiretroviral therapy despite recent guidelines for HIV patients retained in care. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 564-569.	0.6	10
123	Five-Year Mortality for Adults Entering Human Immunodeficiency Virus Care Under Universal Early Treatment Compared With the General US Population. <i>Clinical Infectious Diseases</i> , 2022, 75, 867-874.	2.9	10
124	Impact of Practice Changes on an Antiretroviral Budget in an HIV Care Program. <i>Disease Management and Health Outcomes</i> , 2005, 13, 209-217.	0.3	9
125	Participation in HIV Research: The Importance of Clinic Contact Factors. <i>AIDS Patient Care and STDs</i> , 2008, 22, 619-625.	1.1	9
126	Increasing HIV Subtype Diversity in Canadian-Born Patients Living in Southern Alberta, Canada. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 57, e27-e29.	0.9	9

#	ARTICLE	IF	CITATIONS
127	Missing Data on the Estimation of the Prevalence of Accumulated Human Immunodeficiency Virus Drug Resistance in Patients Treated With Antiretroviral Drugs in North America. <i>American Journal of Epidemiology</i> , 2011, 174, 727-735.	1.6	9
128	An Emerging Concern—High Rates of Frailty among Middle-aged and Older Individuals Living with HIV. <i>Canadian Geriatrics Journal</i> , 2019, 22, 190-198.	0.7	9
129	A picture is worth a thousand words: maps of HIV indicators to inform research, programs, and policy from NA—ACCORD and CCASAnet clinical cohorts. <i>Journal of the International AIDS Society</i> , 2016, 19, 20707.	1.2	8
130	Evaluating medical conferences: the emerging need for a quality metric. <i>Scientometrics</i> , 2020, 122, 759-764.	1.6	8
131	Determinants of risk-taking in HIV-associated neurocognitive disorders.. <i>Neuropsychology</i> , 2017, 31, 798-810.	1.0	8
132	Effect of acyclovir on the uptake of ¹³¹ I-labelled 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)-5-iodouracil in herpes infected cells. <i>Journal of Medical Virology</i> , 1987, 22, 183-188.	2.5	7
133	Comparison of healthcare costs between local and immigrant HIV populations living in Southern Alberta, Canada. <i>Health Policy</i> , 2011, 103, 124-129.	1.4	7
134	Mechanisms by Which Interleukin-12 Corrects Defective NK Cell Anticryptococcal Activity in HIV-Infected Patients. <i>MBio</i> , 2016, 7, .	1.8	7
135	Evaluation of A Phylogenetic Pipeline to Examine Transmission Networks in A Canadian HIV Cohort. <i>Microorganisms</i> , 2020, 8, 196.	1.6	7
136	Gastrointestinal Viral Load and Enteroendocrine Cell Number Are Associated with Altered Survival in HIV-1 Infected Individuals. <i>PLoS ONE</i> , 2013, 8, e75967.	1.1	6
137	Clinical Effectiveness of Integrase Strand Transfer Inhibitor—Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada. <i>Clinical Infectious Diseases</i> , 2020, 73, e1408-e1414.	2.9	6
138	A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infection. <i>PLoS ONE</i> , 2017, 12, e0176282.	1.1	6
139	Seroprevalence of Cytomegalovirus, <i>Toxoplasma gondii</i> , Syphilis, and Hepatitis B and C Virus Infections in a Regional Population Seropositive for HIV Infection. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 1998, 9, 209-214.	0.3	5
140	The Use of Antiretroviral Agents in Patients with Renal Insufficiency. <i>AIDS Patient Care and STDs</i> , 1999, 13, 517-526.	1.1	5
141	Predictors of survival and eradication of <i>Mycobacterium avium</i> complex bacteremia (MAC) in AIDS patients in the Canadian Randomized MAC Treatment Trial. <i>Aids</i> , 1999, 13, 575-582.	1.0	5
142	Similar Challenges with Retention in Care Issues. <i>Clinical Infectious Diseases</i> , 2007, 45, 1527-1527.	2.9	5
143	A Case of Long-Term Seronegative Human Immunodeficiency Virus (HIV) Infection: The Importance of the Humoral Response to HIV. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofv209.	0.4	5
144	Maintaining the continuity of HIV-care records for patients transferring care between centers: challenges, workloads, needs and risks. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016, 28, 1073-1078.	0.6	5

#	ARTICLE	IF	CITATIONS
145	Effect of incident hepatitis C infection on CD4+ cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohort. <i>Aids</i> , 2019, 33, 327-337.	1.0	5
146	Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy. <i>Aids</i> , 2022, 36, 277-286.	1.0	5
147	Canadian Expert Panel Recommendations on the Management of CNS Symptoms Related to Efavirenz. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 2001, 12, 20C-30C.	0.3	4
148	Interpersonal Violence and Its Impact on Persons Living With HIV: A Social Work Response. <i>Journal of HIV/AIDS and Social Services</i> , 2015, 14, 308-318.	0.7	4
149	Identifying Risk of Viral Failure in Treated HIV-Infected Patients Using Different Measures of Adherence: The Antiretroviral Therapy Cohort Collaboration. <i>Journal of Clinical Medicine</i> , 2018, 7, 328.	1.0	4
150	Predictive variables for peripheral neuropathy in treated HIV type 1 infection revealed by machine learning. <i>Aids</i> , 2021, 35, 1785-1793.	1.0	4
151	Reconstructing SARS-CoV-2 infection dynamics through the phylogenetic inference of unsampled sources of infection. <i>PLoS ONE</i> , 2021, 16, e0261422.	1.1	4
152	LIMITATIONS OF OPT-OUT HIV SCREENING AND MOTHER-TO-CHILD HIV TRANSMISSION. <i>American Journal of Public Health</i> , 2010, 100, 388-389.	1.5	3
153	The Impact of Transfer Patients on the Local Cascade of HIV Care Continuum. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 236-240.	0.9	3
154	Healthcare contacts among patients lost to follow-up in HIV care: review of a large regional cohort utilizing electronic health records. <i>International Journal of STD and AIDS</i> , 2017, 28, 1275-1281.	0.5	3
155	HIV diagnosed after 50 years of age. <i>Cmaj</i> , 2020, 192, E255-E255.	0.9	3
156	Schistosoma and Strongyloides screening in migrants initiating HIV Care in Canada: a cross sectional study. <i>BMC Infectious Diseases</i> , 2020, 20, 76.	1.3	3
157	Secular Trends in Breast Cancer Risk Among Women With HIV Initiating ART in North America. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 663-670.	0.9	3
158	Do contemporary antiretrovirals increase the risk of end-stage liver disease? Signals from patients starting therapy in the North American AIDS Cohort Collaboration on Research and Design. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 214-224.	0.9	3
159	Functional relevance of nonsynonymous mutations in the HIV-1 tat gene within an epidemiologically-linked transmission cohort. <i>Virology Journal</i> , 2007, 4, 107.	1.4	2
160	In Defense of Baseline Genotypic Antiretroviral Resistance Testing. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, e1-e2.	0.9	2
161	The costs of antiretroviral drug wastage. <i>Aids</i> , 2000, 14, 616-617.	1.0	2
162	HIV-Related Non-Hodgkin's Lymphoma in Calgary. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 1996, 7, 115-120.	0.3	1

#	ARTICLE	IF	CITATIONS
163	Costing implications of recent treatment interruption studies. <i>Aids</i> , 2006, 20, 2239-2240.	1.0	1
164	The oncology impact of highly active antiretroviral therapy. <i>Journal of Oncology Pharmacy Practice</i> , 2007, 13, 17-25.	0.5	1
165	Myocardial Infarction in HIV-Infected Persons: Time to Focus on the Silent Elephant in the Room?. <i>Clinical Infectious Diseases</i> , 2015, 60, 1424-5.	2.9	1
166	Protecting the health of children moving to Canada. <i>Lancet, The</i> , 2019, 394, 1901-1902.	6.3	1
167	Longitudinal evaluation of risk factors and outcomes of blood stream infections due to <i>Staphylococcus</i> species in persons with HIV: An observational cohort study. <i>EClinicalMedicine</i> , 2021, 31, 100675.	3.2	1
168	Plasma microRNAs are associated with domain-specific cognitive function in people with HIV. <i>Aids</i> , 2021, 35, 1795-1804.	1.0	1
169	Association of the VACS Index with hospitalization among people with HIV in the NA-ACCORD. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, 9-18.	0.9	1
170	Transmission of human immunodeficiency virus (HIV) to a family caregiver through a conjunctival blood splash. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 742-744.	1.0	1
171	Pooch protease paunch. <i>Lancet, The</i> , 1999, 353, 2078.	6.3	0
172	Mortality in migrants with HIV in western Europe. <i>Lancet HIV,the</i> , 2015, 2, e508-e509.	2.1	0
173	Identification and root cause analysis of aberrant CD4+ cell counts in an HIV cohort: the importance of quality control in changing laboratory procedure. <i>Aids</i> , 2020, 34, 1869-1873.	1.0	0
174	Longitudinal analysis of HIV outcomes for persons living with HIV in non-urban areas in southern Alberta, Canada. <i>Jammi</i> , 2022, 7, 44-53.	0.3	0